Search 

Meet Epitopia at the UK Pavilion (Hall B, Stand 2348).

Epitopea is a recently established cancer immunotherapeutics company based in Cambridge (UK) and Montreal(Canada). We are translating the work of our scientific founders, Claude Perreault and Pierre Thibault who asked: what unique features of cancer cells are visible to T cells and can be targeted for immunotherapies? Using immunopetidomics, our founders discovered mutation-containing tumour-specific antigens (TSAs) detectable by mass spec are rare and dramatically outnumbered by aberrantly expressed or cryptic TSAs arising from a variety of dysregulations common in cancer, such as alternative splicing, dysregulated epigenetic control and loss of translational fidelity. These TSAs have a far greater chance of being shared between patients than mutation-containing TSAs; furthermore, emerging results indicate a great many of them are immunogenic and that they are likely to be amongst the targets exploited by immune checkpoint blockade. Epitopea intends to define and develop a pipeline of therapeutic vaccines for durable cancer control.

Meet Fusion Antibodies at the UK Pavilion (Hall B, Stand 2348).

Fusion Antibodies is a contract research organisation, which designs, and optimizes therapeutic antibodies for the healthcare market. We help clients solve complex, challenging problems throughout their early discovery antibody programs. Our expertise is defined by our experience. Unique process frameworks, and technology platforms, enable our clients to develop therapeutics within the most challenging modalities and diseases. Guiding clients through early-stage antibody discovery, in the most efficient and effective way, we enable biotechnology and pharmaceutical organizations towards their end-goal – the provision of treatments that improve the lives of patients worldwide.

As an independent team, we offer flexibility and agility that antibody discovery and development programs require. Our approach to projects considers long-term impacts on safety, efficacy, and manufacturability at every stage, de-risking antibody programs and maximizing success. As an early discovery partner, our scientists increase the pace to the clinic by guiding clients to develop the best antibodies possible.

Meet G&L Healthcare Advisors at the UK Pavilion (Hall B, Stand 2348).

G&L Healthcare Advisors uses subject matter expertise and decades of experience gained in every aspect of Regulatory Affairs, Quality Assurance and Clinical Development to meet the challenges faced by healthcare companies globally. From product development and submissions to company-wide change management, we design, implement, and run quality, results-focused outcomes for all our clients. Our innovative solutions and services support clients at all stages of development to deliver meaningful change for the better.

Meet Integrity at the UK Pavilion (Hall B, Stand 2348).

Formed in 1998, Integrity is a Life Science consulting organisation who are passionate about helping customers innovate and advance treatments for the well-being of the society.

We help our clients plan and implement digital strategies and solutions that dramatically accelerate drug and device development, and optimise manufacturing, supply chain and quality processes.

By combining intelligent risk-based thinking with real-world expertise, we efficiently implement and validate digital solutions in accordance with regulatory expectations.

We are proud to have established long-term partnerships with our clients through close working relationships and successful outcomes. These partnerships continue to provide valuable insights which we carry with us as we navigate the changing business landscape.

We are your partner and your expert, helping you implement the right projects in the right way–delivering change you can trust.